Summary
The claims are about approval/market introduction timing and are not supported or evaluated by the provided prescribing information excerpts (Warnings/Precautions, Dosage, Indications, Adverse Reactions). No on-label approval date information is included in the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
Apixaban (Eliquis) was approved and put on the market in 2012.
The provided FDA prescribing information excerpts do not include approval year or market introduction timing.
Eliquis (apixaban) received approval from the U.S. FDA in 2012.
The provided FDA prescribing information excerpts do not include FDA approval date/year.
Contradictions
Important Omissions
Any label-supported reference for FDA approval year/initial market approval timing for Eliquis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No treatment decisions, dosing, contraindications, warnings, or safety instructions were provided in the AI claims; only an approval-timing assertion was made, which is not supported by the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Approval/market introduction year (2012) is not supported by the provided prescribing information excerpts.
Suggested Improvement
Remove or revise approval-year/market-introduction timing claims unless the FDA label text provided includes an explicit approval date/year to support the statement.